脾多肽联合放疗对中晚期食管癌近期疗效及其对T淋巴细胞亚群水平的影响  

Effect of spleen polypeptide combined with radiotherapy on the short-term efficacy of advanced esophageal carcinoma and its influence on the level of T lymphocyte subsets

作　　者：宋先璐[1] 石兴源[1] 温月凤[1] 周同冲[1] 

机构地区：[1]广州医科大学附属肿瘤医院放疗科,510095

出　　处：《疑难病杂志》2016年第9期939-942,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的观察脾多肽联合放疗对中晚期食管癌近期疗效及其对T淋巴细胞亚群水平的影响。方法选择2011年7月—2015年7月广州医科大学附属肿瘤医院放疗科住院的中晚期食管癌患者79例为研究对象,按照治疗方法不同分为对照组(n=38)与观察组(n=41)。对照组仅采用放射治疗,观察组在此基础上加用脾多肽注射液治疗。比较2组临床疗效、生活质量及T细胞亚群相关指标水平。结果(1)观察组临床缓解率(RR)及临床控制率(DCR)分别为63.41%及85.37%,均高于对照组的47.37%及76.32%,差异有统计学意义(χ~2=5.291、3.783,P=0.029、0.040);(2)治疗后观察组白细胞正常、KPS评分增加、食管疼痛缓解、食欲改善及体质量增加患者比例均显著高于对照组(χ~2=8.928、11.938、6.672、5.383、14.599,P=0.018、0.008、0.027、0.032、0.007);(3)与治疗前比较,治疗后观察组患者CD3^+、CD4^+及CD4^+/CD8^+水平均显著升高,CD8^+显著降低(t=5.102、6.019、7.187、4.334,P=0.028、0.022、0.017、0.032),而对照组均无显著变化(P>0.05);观察组患者治疗后各项指标改善均优于对照组(t=3.309、4.403、3.872、5.182,P=0.042、0.031、0.038、0.027)。结论脾多肽联合放疗治疗中晚期食管癌近期临床疗效较为显著,其可能通过改变患者T淋巴细胞亚群水平而发挥作用。Objective To observe the short-term curative effect of spleen polypeptide combined with radiotherapy on advanced esophageal carcinoma and its effect on the level of T lymphocyte subsets .Methods From July 2011 to July 2015 , in the Department of radiotherapy; Affiliated Tumor Hospital of Guangzhou Medical College , 79 cases of advanced esophageal carcinoma hospitalized patients were enrolled as the research object , according to the different treatment method , they were di-vided into control group （ n =38） and observation group （ n =41）.The control group was treated with radiotherapy only , and the observation group was treated with Lienal Polypeptide Injection on the basis of the observation group .Compare the clinical efficacy, quality of life and the level of T cell subsets in the 2 groups.Results （1） The clinical remission rate and the clinical control rate （DCR） of observation group （RR） were 63.41%and 85.37%, 47.37%and 76.32%, which were higher than the control group, the difference was statistically significant （χ^2 =5.291,χ^2 =3.783;P =0.029, P =0.040）;（2） After treatment, the observation group of normal white blood cells , KPS score increased, esophageal pain relief , im-proved appetite and body weight increased the proportion of patients were significantly higher than those in control group （χ^2 =8 .928 ,χ^2 =11 .938 ,χ^2 =6 .672 ,χ^2 =5 .383 ,χ^2 =14 .599;P =0 .018 , P =0 .008 , P =0 .027 , P =0 .032 , P =0 .007 ）;（3） Compared with before treatment , after treatment, the patients in the observation group CD3^＋, CD4^＋and the level of CD4^＋/CD8^＋increased significantly, CD8 ＋decreased significantly （ t =5.102,6.019,7.187,4.334, P =0.028,0.022, 0.017,0.032）, while the control group showed no significant change （ P 〉0.05）; patients in the observation group after treatment the indicators were better than the control group （ t =3.309, t =4.403, t =3.872, t =5.182;P =0.042, P =0.031, P =0.038, P =0.027）.Conclusion Spleen polypeptide combined

关 键 词：脾多肽 放疗 食管癌 疗效 T淋巴细胞亚群 

分 类 号：R735.1[医药卫生—肿瘤]